Similarly, KRAS mutations confer the constitutive activation of this oncogene, stimulating cell proliferation, inducing autophagy, suppressing apoptosis, altering cell metabolism, changing cell motility and invasion, and modulating the tumor microenvironment [28]. Here, KRAS is linked to neoplasm.